The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).

Inclusion Criteria:

• Male or Female
• The subject is an out-patient
• Age 30 years or above
• Dyskinesias present during more than 25% of the waking day
• Dyskinesias at least moderately disabling
• Written informed consent

Exclusion Criteria:

• Pregnancy and/or lactation
• Participation in another study within the last 30 days
• Dementia or other psychiatric illness that prevents provision of informed consent
• History of allergic disorders such as asthma
• Known hypersensitivity to the study treatment(s)
• Known hypersensitivity to ACTH